Laboratory for Molecular Diagnostics
Center for Nephrology and Metabolic Disorders

cGMP-inhibited 3',5'-cyclic phosphodiesterase A

The PDE3A gene encodes an enzyme that regulates the life cycle of cyclic cGMP and cAMP in cells. Mutations cause autosomal dominant brachydactyly with hypertension.

Genetests:

Clinic Method Carrier testing
Turnaround 5
Specimen type genomic DNA
Clinic Method Genomic sequencing of the entire coding region
Turnaround 25
Specimen type genomic DNA

Related Diseases:

Hypertension and brachydactyly syndrome
PDE3A

References:

1.

Meacci E et. al. (1992) Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase.

[^]
2.

Bilginturan N et. al. (1973) Hereditary brachydactyly associated with hypertension.

[^]
3.

Tang KM et. al. (1997) Expression and mutagenesis of the catalytic domain of cGMP-inhibited phosphodiesterase (PDE3) cloned from human platelets.

[^]
4.

Lefièvre L et. al. (2002) Presence of cyclic nucleotide phosphodiesterases PDE1A, existing as a stable complex with calmodulin, and PDE3A in human spermatozoa.

[^]
5.

Masciarelli S et. al. (2004) Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility.

[^]
6.

Maass PG et. al. (2015) PDE3A mutations cause autosomal dominant hypertension with brachydactyly.

[^]
Update: Sept. 26, 2018